DelveInsight’s “Huntington’s Disease Market Insights, Epidemiology, and Market Forecast-2036” report delivers an in-depth understanding of the Huntington’s Disease, historical and forecasted epidemiology as well as the Huntington’s Disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Discover Key Insights into the Huntington’s Disease Market with DelveInsight’s In-Depth Report @ Huntington’s Disease Market Size
Key Takeaways from the Huntington’s Disease Market Report
- In January 2026, Skyhawk Therapeutics reported positive results from a nine-month interim analysis of its Phase I trial evaluating SKY-0515 for Huntington’s Disease.
- In March 2025, PTC Therapeutics announced results from the Phase II PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington’s disease patients. The study met its primary endpoint of reduction in blood Huntingtin (HTT) protein levels (p<0.0001) at Week 12 and favorable safety and tolerability. In addition, the 12-month data from the Stage 2 patients are consistent with the previously reported dose-dependent lowering of HTT protein and dose-dependent trends across clinical scales.
- The Huntington’s Disease market size was valued at USD 320 million in 2025 and is projected to grow at a CAGR of 14% during the forecast period from 2026 to 2036.
- In the United States, the total number of prevalent cases of Huntington’s disease was 44,000 in 2025, which is expected to increase during the forecast period, i.e., 2026–2036.
- In 2025, the total prevalent cases of Huntington’s disease were 37,000 in EU4 and the UK, which are projected to increase during the forecast period, i.e., 2026–2036.
- In the 7MM, Huntington’s Disease is more prevalent in individuals aged ≥60 years, accounting for approximately 50% of total cases.
- Findings from various secondary studies suggest that Huntington’s disease is more prevalent in the elderly population.
- In 2025, 80 Stage IV cases of Huntington’s disease and 20 Stage V cases of Huntington’s disease were estimated for Japan, as fewer people are identified in advanced stages.
- Huntington’s disease is a rare, inherited, progressive brain disorder caused by a mutation in the HTT gene on chromosome 4, following an autosomal dominant pattern, meaning individuals who inherit the faulty gene will develop the disease.
- The leading Huntington’s Disease Companies such as Teva Pharmaceuticals, Neurocrine Biosciences, Novartis Pharmaceuticals, Skyhawk Therapeutics, Alnylam Pharmaceuticals, Roche, UniQure Biopharma, and others.
- Promising Huntington’s Disease Therapies such as AUSTEDO, INGREZZA, SKY-0515, Votoplam (PTC518), Pridopidine, ANX005, and others.
Stay ahead in the Huntington’s Disease Therapeutics Market with DelveInsight’s Strategic Report @ Huntington’s Disease Market Outlook
Huntington’s Disease Epidemiology Segmentation in the 7MM
- Total Prevalent Cases of Huntington’s Disease
- Total Diagnosed Prevalent Cases of Huntington’s Disease
- Age-specific Cases of Huntington’s Disease
- Stage-specific Cases of Huntington’s Disease
- Total Treated Cases of Huntington’s Disease
Download the report to understand which factors are driving Huntington’s Disease Epidemiology trends @ Huntington’s Disease Prevalence
Marketed Huntington’s Disease Therapies
- AUSTEDO (Deutetrabenazine): Teva Pharmaceuticals AUSTEDO is a deuterated form of a small molecule inhibitor of vesicular monoamine 2 transporter, or VMAT2, that is designed to regulate the levels of dopamine in the brain. It is indicated in adults for the treatment of Chorea associated with Huntington’s disease. The FDA granted AUSTEDO New Chemical Entity Exclusivity until April 2022 and Orphan Drug exclusivity for the treatment of chorea associated with Huntington disease until April 2024. In May 2024, Teva Pharmaceuticals announced that the US FDA approved AUSTEDO XR as a one-pill, once-daily treatment option with four new tablet strengths (30, 36, 42, 48 mg). In 2025, the highest revenue was captured by AUSTEDO, accounting for USD 167 million.
- INGREZZA (valbenazine): Neurocrine Biosciences INGREZZA is a selective VMAT2 inhibitor, believed to work by reducing the amount of dopamine released in a region of the brain that controls movement and motor function. In August 2023, the FDA granted approval for INGREZZA capsules to treat chorea in adults with Huntington’s disease. The FDA approval is supported by data from two clinical studies conducted in collaboration with the Huntington Study Group (HSG), including the KINECT-HD Phase III study and the ongoing KINECT-HD2 open-label extension trial.
- Tetrabenazine: Available as Generics Tetrabenazine is approved for treating chorea and works alongside Deutetrabenazine as a cornerstone therapy for managing movement disorders in Huntington’s disease. It is widely available as a generic medication.
Emerging Huntington’s Disease Therapies
- SKY-0515: Skyhawk Therapeutics SKY-0515 is an orally-administered, investigational small molecule RNA modulator developed through the company’s novel RNA-modulating platform, SKYSTAR. SKY-0515 therapeutically reduces both HTT protein and PMS1 protein. PMS1 is an additional key driver of somatic CAG repeat expansion and HD pathology and should complement the benefits of reducing mutant HTT. Skyhawk’s SKY-0515 Phase II/III FALCON-HD trial has expanded worldwide and has treated more than 90 patients. In January 2026, Skyhawk Therapeutics reported positive results from a nine-month interim analysis of its Phase I trial. In September 2025, the first interim analysis of the Part C patient cohort demonstrated dose-dependent reductions of mHTT protein in blood, including 62% at the 9mg dose at Day 84.
- Votoplam (PTC518): Novartis Pharmaceuticals PTC518 is a small molecule splicing modifier that acts via a unique mechanism to promote the inclusion of a novel pseudoexon containing a premature termination codon, thus triggering Huntingtin (HTT) mRNA degradation and subsequent reduction in HTT protein levels. In March 2025, PTC Therapeutics announced results from the Phase II PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington’s disease patients. The study met its primary endpoint of reduction in blood Huntingtin (HTT) protein levels (p<0.0001) at Week 12 and favorable safety and tolerability. In December 2024, Novartis announced that it had entered into a global license and collaboration agreement with PTC Therapeutics for PTC518.
To know more about Huntington’s Disease treatment guidelines, visit @ Huntington’s Disease Treatment Market Landscape
Huntington’s Disease Therapies and Companies
- AUSTEDO: Teva Pharmaceuticals
- INGREZZA: Neurocrine Biosciences
- SKY-0515: Skyhawk Therapeutics
- Votoplam (PTC518): Novartis Pharmaceuticals
- Pridopidine: Various
- ANX005: Various
- Gene-targeting therapies: Alnylam Pharmaceuticals, Roche, UniQure Biopharma
Huntington’s Disease Market Dynamics
The Huntington’s disease market dynamics have undergone significant changes over the years. Despite advances in understanding disease pathology, treatment remains largely symptomatic, with no curative options currently available, highlighting a significant unmet medical need. The growing focus on genetic and biomarker-driven approaches, including mutant huntingtin (mHTT) lowering strategies, is shaping the future treatment paradigm and enabling earlier intervention. The therapeutic landscape is evolving with the development of gene therapies, antisense oligonucleotides, and RNA-based approaches aimed at slowing disease progression rather than only managing symptoms. Increasing research investments, patient advocacy, and clinical trial activity are accelerating innovation, while improved disease awareness and enhanced genetic testing capabilities are supporting earlier diagnosis and patient management, expected to drive market expansion over the forecast period.
Learn more about the FDA-approved drugs for Huntington’s Disease @ Drugs for Huntington’s Disease Treatment
Scope of the Huntington’s Disease Market Report
- Coverage- 7MM
- Study Period- 2022-2036
- Huntington’s Disease Companies- Teva Pharmaceuticals, Neurocrine Biosciences, Novartis Pharmaceuticals, Skyhawk Therapeutics, Alnylam Pharmaceuticals, Roche, UniQure Biopharma, and others
- Huntington’s Disease Therapies- AUSTEDO, INGREZZA, SKY-0515, Votoplam (PTC518), Pridopidine, ANX005, and others
- Huntington’s Disease Unmet Needs, KOL’s views, Analyst’s views, Huntington’s Disease Market Access and Reimbursement
Table of Content
- Key Insights
- Report Introduction
- Executive Summary
- Key Events
- Epidemiology and Market Forecast Methodology
- Huntington’s Disease Market Overview at a Glance
- Disease Background and Overview of Huntington’s Disease
- Treatment and Management of Huntington’s Disease
- Patient Journey of Huntington’s Disease
- Epidemiology and Patient Population of Huntington’s Disease
- Marketed Drugs
- Emerging Drugs
- Huntington’s Disease: 7MM Market Analysis
- Unmet Needs of Huntington’s Disease
- SWOT Analysis of Huntington’s Disease
- KOL Views of Huntington’s Disease
- Market Access and Reimbursement of Huntington’s Disease
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk
